Hepatic Steatosis
Hepatic steatosis identified in more than half of younger adults without history of MASLD
Hepatic steatosis was prevalent among 52% of adults with or without type 2 diabetes and no known history of metabolic dysfunction-associated steatotic liver disease, according to findings published in Obesity.
Women with food insecurity, low BMI more likely to have hepatic steatosis
BOSTON — Women who experience food insecurity and have a BMI less than 25 kg/m2 had higher odds of hepatic steatosis compared with overweight women or those with obesity, regardless of HIV status, according to research at The Liver Meeting.
Steatosis present in most adults with type 1 diabetes and overweight or obesity
Hepatic steatosis may be present in most adults with type 1 diabetes, especially those with overweight or obesity, according to a study published in Journal of Diabetes and Its Complications.
Long, irregular menstrual cycles may increase NAFLD risk for premenopausal women
Premenopausal women with long or irregular menstrual cycles have a higher risk for prevalent and incident nonalcoholic fatty liver disease compared with women with normal cycles, according to study findings.
Pegbelfermin improves markers of fibrosis in NASH
Pegbelfermin was safe and effective in improving markers of steatosis, fibrosis and inflammation among patients with nonalcoholic steatohepatitis with stage 3 fibrosis, according to a presentation at The Liver Meeting Digital Experience.
Hepatic steatosis common in patients with severe hypertriglyceridemia
Among patients with severe hypertriglyceridemia who underwent MRI proton density fat fraction, clinically meaningful hepatic steatosis appeared to be common, according to a presenter at the National Lipid Association Scientific Sessions.
World Trade Center early responders have increased hepatic steatosis
Increased hepatic steatosis was observed among responders who arrived earlier at the World Trade Center site, according to a study published in American Journal of Industrial Medicine.
Low-carb high-fat, intermittent fasting diets reduce more hepatic steatosis in NAFLD
Researchers saw higher reduction in steatosis and body weight with the low-carb high-fat and 5:2 diets compared with the standard of care in patients with nonalcoholic fatty liver disease, according to a presentation at the International Liver Congress.
VIDEO: Risk for liver damage may be associated with RA
In this video, Jeffrey A. Sparks, MD, MMSc, associate physician at Brigham and Women's Hospital, explained findings from a study exploring metabolic issues and rheumatoid arthritis.
Novel antisense drug shows promise in hypertriglyceridemia, diabetes, NAFLD
Vupanorsen, an investigational antisense therapy, reduced triglyceride levels at 6 months and demonstrated benefit on additional lipid parameters compared with placebo in patients with hypertriglyceridemia, diabetes and hepatic steatosis.